Leyla Diaz is a prominent inventor based in Indianapolis, IN (US). She has made significant contributions to the field of vaccine development, particularly in the inactivation of viruses. Her innovative approach has the potential to enhance the safety and efficacy of vaccines.

Latest Patents

Leyla Diaz holds a patent for the invention titled "Inactivation of viruses by delipidation." This invention relates to vaccines containing enveloped viruses whose envelopes have been depleted of lipids using methyl β-cyclodextrin (MBCD). The delipidation process abolishes the infectivity of those viruses, allowing delipidated viruses to be used safely in vaccines. The method results in viruses with less than 20% of the cholesterol of an untreated virus while retaining at least 85% of the protein content. This innovative approach preserves the immunogenicity of the viral proteins, representing a new alternative for generating inactivated viruses for effective vaccines.

Career Highlights

Leyla Diaz is currently employed at Elanco US Inc., where she continues to work on groundbreaking research in the field of vaccine development. Her dedication to innovation has positioned her as a key figure in her organization.

Collaborations

Leyla collaborates with Stephen Wu, a fellow researcher, to further advance their work in vaccine technology. Their partnership exemplifies the importance of teamwork in scientific research.

Conclusion

Leyla Diaz is an influential inventor whose work in vaccine development is paving the way for safer and more effective vaccines. Her innovative methods and dedication to research are making a significant impact in the field.

Profile summary based on public USPTO records.